IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas

Hengrui’s Phase 1 IDE849 study reported a 17.4-month median overall survival and 72.5% ORR in second-line SCLC (n=51); across previously treated SCLC (n=101), median OS was 14.7 months and ORR was 68.3%. At the 2.4 mg/kg expansion dose, Grade ≥3 treatment-related adverse events occurred in 33.3%, while treatment-related discontinuation was 2.5% across the 122-patient study. IDEAYA is targeting two global Phase 3 trials in post-Imdelltra ES-SCLC and NEC following FDA Type C meetings; the results are early, from a Phase 1 study, and require confirmation in later trials.

Analysis

The key read-through is validation of a DLL3-directed ADC in relapsed disease—not proof of a survival advantage. The China Phase 1 signal is encouraging, but pooled doses, a single-arm design, modest cohorts and unconfirmed responses limit cross-trial comparison. The 2L OS estimate is especially vulnerable to patient selection and follow-up effects. For IDEAYA (IDYA), the value inflection is whether its global study reproduces activity and establishes a tolerable recommended dose in post-Imdelltra patients; the small global safety cohorts do not yet settle the dose question, given the different observed Grade ≥3 TRAE rates at 2.4 and 3.5 mg/kg.

Competition is a second-order risk: post-Imdelltra development must show meaningful activity after a DLL3-directed therapy, not merely in broader relapsed SCLC. Amgen’s Imdelltra sets a treatment and efficacy benchmark; IDE849’s distinct ADC mechanism could offer an alternative, but resistance biology and sequencing remain unproven. Cytopenias and ILD warrant attention as exposure grows. The NEC opportunity is plausible but the 19-patient signal is exploratory; incidence estimates are not an addressable-market forecast.

Near term, the release may support sentiment, but the material catalyst is IDEAYA’s global efficacy/safety update targeted for year-end 2026 or early 2027, followed by Phase 3 execution. FDA Type C feedback is not trial-design acceptance. Contrarian view: the market may overvalue preliminary OS and broad market estimates while underweighting post-Imdelltra efficacy, dose selection and randomized-trial risk. No reliable valuation or consensus data are provided to assess how much is priced in.

Key Decisions for Investors

• IDYA: Avoid chasing a sharp announcement-driven gap. Consider only a small, defined-risk event position after price discovery; add exposure only if the global update shows credible efficacy in post-Imdelltra SCLC at a tolerable selected dose. The thesis is falsified by weak global response/duration or a dose-limiting safety profile.
• Treat the year-end 2026/early-2027 global update as the principal 1–3 month catalyst window. Track confirmed response and response duration by prior-treatment subgroup, dose-specific Grade ≥3 toxicity, discontinuations, and the selected Phase 3 dose—not headline ORR alone.
• Do not trade AZN on the mention of durvalumab: the combination is exploratory, with no combination efficacy data here. Revisit only if IDEAYA reports a credible combination signal or a specific development commitment.
• Keep Amgen’s Imdelltra as a competitive benchmark, not a direct short: IDE849’s post-Imdelltra efficacy, sequencing, and comparative tolerability are not established. A meaningful deterioration in the Imdelltra standard of care could change the opportunity, but is not demonstrated by this update.